Literature DB >> 21807909

Salmonella enterica serovar enteritidis core O polysaccharide conjugated to H:g,m flagellin as a candidate vaccine for protection against invasive infection with S. enteritidis.

Raphael Simon1, Sharon M Tennant, Jin Y Wang, Patrick J Schmidlein, Andrew Lees, Robert K Ernst, Marcela F Pasetti, James E Galen, Myron M Levine.   

Abstract

Nontyphoidal Salmonella enterica serovars Enteritidis and Typhimurium are a common cause of gastroenteritis but also cause invasive infections and enteric fever in certain hosts (young children in sub-Saharan Africa, the elderly, and immunocompromised individuals). Salmonella O polysaccharides (OPS) and flagellar proteins are virulence factors and protective antigens. The surface polysaccharides of Salmonella are poorly immunogenic and do not confer immunologic memory, limitations overcome by covalently attaching them to carrier proteins. We conjugated core polysaccharide-OPS (COPS) of Salmonella Enteritidis lipopolysaccharide (LPS) to flagellin protein from the homologous strain. COPS and flagellin were purified from a genetically attenuated (ΔguaBA) "reagent strain" (derived from an isolate from a patient with clinical bacteremia) engineered for increased flagellin production (ΔclpPX). Conjugates were constructed by linking flagellin monomers or polymers at random COPS hydroxyls with various polysaccharide/protein ratios by 1-cyano-4-dimethylaminopyridinium tetrafluoroborate (CDAP) or at the 3-deoxy-d-manno-octulosonic acid (KDO) terminus by thioether chemistry. Mice immunized on days 0, 28, and 56 with COPS-flagellin conjugates mounted higher anti-LPS IgG levels than mice receiving unconjugated COPS and exhibited high antiflagellin IgG; anti-LPS and antiflagellin IgG levels increased following booster doses. Antibodies generated by COPS-flagellin conjugates mediated opsonophagocytosis of S. Enteritidis cells into mouse macrophages. Mice immunized with flagellin alone, COPS-CRM₁₉₇, or COPS-flagellin conjugates were significantly protected from lethal challenge with wild-type S. Enteritidis (80 to 100% vaccine efficacy).

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21807909      PMCID: PMC3187246          DOI: 10.1128/IAI.05484-11

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  73 in total

Review 1.  Mouse models to assess the efficacy of non-typhoidal Salmonella vaccines: revisiting the role of host innate susceptibility and routes of challenge.

Authors:  Raphael Simon; Sharon M Tennant; James E Galen; Myron M Levine
Journal:  Vaccine       Date:  2011-05-25       Impact factor: 3.641

2.  Physical and chemical characterization and immunologic properties of Salmonella enterica serovar typhi capsular polysaccharide-diphtheria toxoid conjugates.

Authors:  Changfa Cui; Rodney Carbis; So Jung An; Hyun Jang; Cecil Czerkinsky; Shousun C Szu; John D Clemens
Journal:  Clin Vaccine Immunol       Date:  2009-11-04

3.  Activation of soluble polysaccharides with 1-cyano-4-dimethylaminopyridinium tetrafluoroborate for use in protein-polysaccharide conjugate vaccines and immunological reagents.

Authors:  A Lees; B L Nelson; J J Mond
Journal:  Vaccine       Date:  1996-02       Impact factor: 3.641

4.  Cutting edge: repurification of lipopolysaccharide eliminates signaling through both human and murine toll-like receptor 2.

Authors:  M Hirschfeld; Y Ma; J H Weis; S N Vogel; J J Weis
Journal:  J Immunol       Date:  2000-07-15       Impact factor: 5.422

5.  Clinical presentation of non-typhoidal Salmonella bacteraemia in Malawian children.

Authors:  S M Graham; A L Walsh; E M Molyneux; A J Phiri; M E Molyneux
Journal:  Trans R Soc Trop Med Hyg       Date:  2000 May-Jun       Impact factor: 2.184

6.  Phase 1 and phase 2 studies of Salmonella enterica serovar paratyphi A O-specific polysaccharide-tetanus toxoid conjugates in adults, teenagers, and 2- to 4-year-old children in Vietnam.

Authors:  E Y Konadu; F Y Lin; V A Hó; N T Thuy; P Van Bay; T C Thanh; H B Khiem; D D Trach; A B Karpas; J Li; D A Bryla; J B Robbins; S C Szu
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

7.  Versatile and efficient synthesis of protein-polysaccharide conjugate vaccines using aminooxy reagents and oxime chemistry.

Authors:  Andrew Lees; Goutam Sen; Alberto LopezAcosta
Journal:  Vaccine       Date:  2005-09-12       Impact factor: 3.641

8.  Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines.

Authors:  Andrew J Pollard; Kirsten P Perrett; Peter C Beverley
Journal:  Nat Rev Immunol       Date:  2009-03       Impact factor: 53.106

Review 9.  Quadrivalent meningococcal conjugate vaccines.

Authors:  David Pace; Andrew J Pollard; Nancy E Messonier
Journal:  Vaccine       Date:  2009-05-27       Impact factor: 3.641

10.  Invasive non-typhoidal Salmonella in Mozambican children.

Authors:  Inácio Mandomando; Eusébio Macete; Betuel Sigaúque; Luis Morais; Llorenç Quintó; Jahit Sacarlal; Mateu Espasa; Xavier Vallès; Quique Bassat; Pedro Aide; Tacilta Nhampossa; Sonia Machevo; Joaquim Ruiz; Ariel Nhacolo; Clara Menéndez; Karen L Kotloff; Anna Roca; Myron M Levine; Pedro L Alonso
Journal:  Trop Med Int Health       Date:  2009-09-27       Impact factor: 2.622

View more
  61 in total

1.  Comparing the roles of antibodies to nontyphoidal Salmonella enterica in high- and low-income countries and implications for vaccine development.

Authors:  Calman A MacLennan; Sharon M Tennant
Journal:  Clin Vaccine Immunol       Date:  2013-07-31

Review 2.  Vaccination against Salmonella Infection: the Mucosal Way.

Authors:  Rémi Gayet; Gilles Bioley; Nicolas Rochereau; Stéphane Paul; Blaise Corthésy
Journal:  Microbiol Mol Biol Rev       Date:  2017-06-14       Impact factor: 11.056

Review 3.  Live attenuated vaccines for invasive Salmonella infections.

Authors:  Sharon M Tennant; Myron M Levine
Journal:  Vaccine       Date:  2015-04-19       Impact factor: 3.641

Review 4.  Vaccines for viral and bacterial pathogens causing acute gastroenteritis: Part II: Vaccines for Shigella, Salmonella, enterotoxigenic E. coli (ETEC) enterohemorragic E. coli (EHEC) and Campylobacter jejuni.

Authors:  Miguel O'Ryan; Roberto Vidal; Felipe del Canto; Juan Carlos Salazar; David Montero
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

5.  Synthetic and immunological studies of Salmonella Enteritidis O-antigen tetrasaccharides as potential anti-Salmonella vaccines.

Authors:  Chang-Xin Huo; Debashis Dhara; Scott M Baliban; Setare Tahmasebi Nick; Zibin Tan; Raphael Simon; Anup Kumar Misra; Xuefei Huang
Journal:  Chem Commun (Camb)       Date:  2019-04-11       Impact factor: 6.222

6.  A scalable method for O-antigen purification applied to various Salmonella serovars.

Authors:  F Micoli; S Rondini; M Gavini; I Pisoni; L Lanzilao; A M Colucci; C Giannelli; F Pippi; L Sollai; V Pinto; F Berti; C A MacLennan; L B Martin; A Saul
Journal:  Anal Biochem       Date:  2012-11-07       Impact factor: 3.365

Review 7.  Glycoconjugate vaccine strategies for protection against invasive Salmonella infections.

Authors:  Raphael Simon; Myron M Levine
Journal:  Hum Vaccin Immunother       Date:  2012-02-28       Impact factor: 3.452

8.  Phase 1 testing of detoxified LPS/group B meningococcal outer membrane protein vaccine with and without synthetic CPG 7909 adjuvant for the prevention and treatment of sepsis.

Authors:  Alan S Cross; Nancy Greenberg; Melissa Billington; Lei Zhang; Christopher DeFilippi; Ryan C May; Kanwaldeep K Bajwa
Journal:  Vaccine       Date:  2015-10-26       Impact factor: 3.641

Review 9.  Animal Models for Salmonellosis: Applications in Vaccine Research.

Authors:  Ellen E Higginson; Raphael Simon; Sharon M Tennant
Journal:  Clin Vaccine Immunol       Date:  2016-09-06

10.  Activation of NLRC4 downregulates TLR5-mediated antibody immune responses against flagellin.

Authors:  Wei Li; Jingyi Yang; Ejuan Zhang; Maohua Zhong; Yang Xiao; Jie Yu; Dihan Zhou; Yuan Cao; Yi Yang; Yaoming Li; Huimin Yan
Journal:  Cell Mol Immunol       Date:  2015-04-27       Impact factor: 11.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.